Company News - Press Releases - Events - Publications

Bicoll and the European Molecular Biology Laboratory (EMBL) announce results of their joint research project on the identification of aurora kinase inhibitors

Munich (Germany), Heidelberg (Germany) – June 22, 2010 – BICOLL GmbH, a biopharmaceutical
drug discovery company specializing in high-tech natural product chemistry to identify novel small
molecules for drug discovery and related innovative fields and EMBL, the renowned international and
inter-governmental research organisation, focusing on molecular biology and biophysics, today
announce the successful completion of a joint research project on the identification of active compounds as inhibitors of aurora kinases.

Questions? Get in touch!

We would love talking to you:

Bicoll GmbH
Am Klopferspitz 19
82152 Planegg/Martinsried
+49 (0)89 820 106 30